Innoviva Inc(INVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:25 AM ET (Korea 9/11 17:25)
Full metrics table
| Index | RUT | P/E | 5.02 | EPS (ttm) | 4.1 | Insider Own | 1.25% | Shs Outstand | 72.6M | Perf Week | -3.42% |
| Market Cap | 1.49B | Forward P/E | 8.95 | EPS next Y | -6.68% | Insider Trans | - | Shs Float | 71.3M | Perf Month | -0.63% |
| Enterprise Value | 1.18B | PEG | - | EPS next Q | 0.53 | Inst Own | 104.83% | Short Float | 9.62% | Perf Quarter | -10.35% |
| Income | 0.36B | P/S | 3.28 | EPS this Y | -25.15% | Inst Trans | -1.35% | Short Ratio | 9.09 | Perf Half Y | -8.03% |
| Sales | 0.45B | P/B | 1.21 | EPS next 5Y | -15.8% | ROA | 23.53% | Short Interest | 6.86M | Perf YTD | 3.15% |
| Book/sh | 16.98 | P/C | 2.57 | EPS past 3/5Y | - 10.35% | ROE | 36.68% | 52W High | -18% ($25.15) | Perf Year | 3.77% |
| Cash/sh | 8.02 | P/FCF | 7.86 | Sales past 3/5Y | 325.77% 3.93% | ROIC | 23.78% | 52W Low | 24.82% ($16.52) | Perf 3Y | 63.39% |
| Dividend Est. | - | EV/EBITDA | 5.81 | EPS Y/Y TTM | 693.83% | Gross Margin | 69.98% | Volatility(W/M) | 2.15% 1.82% | Perf 5Y | 32.78% |
| Dividend TTM | - | EV/Sales | 2.6 | Sales Y/Y TTM | 18.17% | Oper. Margin | 35.83% | ATR (14) | 0.48 | Perf 10Y | 83.62% |
| Dividend Ex-Date | 2015/9/8 | Quick Ratio | 15.18 | EPS Q/Q | -247.04% | Profit Margin | 78.72% | RSI (14) | 40.14 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.01 | Sales Q/Q | 18.61% | SMA20 | -2.28% ($21.1) | Beta | 0.38 | Target Price | $35 |
| Payout | - | Debt/Eq | 0.22 | Earnings | 2026/8/5 | SMA50 | -3.36% ($21.34) | Rel Volume | 1.11 | Prev Close | $21.13 |
| Employees | 159 | LT Debt/Eq | 0.22 | EPS/Sales Surpr. | -361.47% 7.75% | SMA200 | -5.29% ($21.77) | Avg Volume(3M) | 0.76M | Price | $20.62 |
| IPO | 2004/10/5 | Option/Short | Yes/Yes | Trades | 10269 | Volume | 836,380 | Change | -2.41% |
Company
INVA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US healthcare company that combines pharmaceutical royalties with a specialty pharmaceuticals business. It generates royalty income from respiratory therapeutics and other products, while also operating acquired specialty pharmaceutical and infectious disease treatment businesses, running a model that combines stable royalty cash flows with specialty pharmaceuticals. The company has established itself as a healthcare operator spanning both royalties and specialty pharmaceuticals.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
INVA makes money exceptionally well
35.83% of revenue is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -25.1% this year.
Tap to view numbers
The stock looks undervalued
Trading at 5.0 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +63.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 104.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PJP 0.03%
SIXS 0.02%
XPH 0.02%
PILL 0.01%
SCOW 0.01%It ranks #4 in the industry
Based on market cap of $1B.
INVA $1B PER 5.0
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is INVA?
INVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INVA?
The market cap of INVA is approximately $1.5B, ranking 2,330 within its sector.
What is the P/E ratio of INVA?
INVA has a P/E ratio of approximately 5.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INVA?
INVA has recorded a 52-week high of $25.15 and a low of $16.52.
